Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 16, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax to Announce Fourth Quarter and Year-end 2016 Financial Results and Host Conference Call and Webcast on March 2, 2017

WALTHAM, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its fourth quarter 2016 financial results on Thursday, March 2, 2017, after the close of...
February 09, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Appoints Richard P. Shea as Chief Financial Officer

WALTHAM, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
January 31, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board

WALTHAM, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
January 05, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors

WALTHAM, Mass., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
December 14, 2016 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer

WALTHAM, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and...
November 21, 2016 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference

WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple...
November 10, 2016 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update

Execution on clinical timelines and advancement of oncology programs continues with initiation of: Phase 2 cohorts of ENCORE 601 in NSCLC and melanomaPhase 1 clinical trial of SNDX-6352 WALTHAM,...
November 08, 2016 09:26 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals to Present at the SITC 31st Annual Scientific Meeting

WALTHAM, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
October 28, 2016 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax to Announce Third Quarter 2016 Financial Results and Host Conference Call and Webcast on November 10, 2016

WALTHAM, Mass., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its third quarter 2016 financial results on Thursday, November 10, 2016, after the...
September 06, 2016 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Announces Participation at Four Upcoming Investor Conferences

WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in...